View Single Post
Old 06-21-2009, 12:27 PM   #1
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
Ipilimumab: controversies in its development, utility and autoimmune adverse events

http://www.springerlink.com/content/...1/fulltext.pdf

An interesting introduction to a drug making big waves right now in prostate cancer.
http://www.minnpost.com/healthblog/2...e_cancer_study

There was a stage IV BC trial but I can't find results.
http://clinicaltrials.gov/show/NCT00083278

Anyway..
I found the focus on side effects as early signal of benefit and possibility that traditional measures of efficacy may prematurely deem drugs like this a failure before they gather steam. The paper suggests response rate is almost doubled when given proper length of trial.
More here: http://www.cancerresearch.org/Programs.aspx?id=2340
Yes...me thinks it ties into cancer stem cells and the issues of judging success.
Rich66 is offline   Reply With Quote